Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Smyth, LM; Piha-Paul, SA; Won, HH; Schram, AM; Saura, C; Loi, S; Lu, J; Shapiro, GI; Juric, D; Mayer, IA; Arteaga, CL; de la Fuente, MI; Brufksy, AM; Spanggaard, I; Mau-Sorensen, M; Arnedos, M; Moreno, V; Boni, V; Sohn, J; Schwartzberg, LS; Gonzalez-Farre, X; Cervantes, A; Bidard, FC; Gorelick, AN; Lanman, RB; Nagy, RJ; Ulaner, GA; Chandarlapaty, S; Jhaveri, K; Gavrila, EI; Zimel, C; Selcuklu, SD; Melcer, M; Samoila, A; Cai, YY; Scaltriti, M; Mann, G; Xu, F; Eli, LD; Dujka, M; Lalani, AS; Bryce, R; Baselga, J; Taylor, BS; Solit, DB; Meric-Bernstam, F; Hyman, DM

CANCER DISCOVERY, 2020; 10 (2): 198

Abstract

HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索